Previously, Wegovy was given as a weekly injection. The pill form provides a daily oral option for obese adults or those overweight with related conditions, used with calorie reduction and more activity. It's also cleared in the US to cut major heart event risks like attacks and strokes in high-risk cases.
Up to this point, Wegovy required weekly injections for administration. This oral pill variant delivers a daily alternative for grown-ups battling obesity or carrying extra weight tied to health complications, meant to support a calorie-restricted meal plan and boosted exercise routines.
Furthermore, in the United States, it's endorsed to diminish the likelihood of significant cardiovascular occurrences, including myocardial infarctions and strokes, among particular patients at elevated risk.
Original source: GULF NEWS
View original article →
New research reveals that pairing GLP-1 receptor agonists with healthy lifestyle habits significantly lowers heart attack, stroke, and CV death risk in type 2 diabetes patients. Those following 6-8 habits plus GLP-1 therapy saw a 43% reduced MACE risk. This study highlights their complementary roles in heart health.
Sciwind Biosciences has secured a landmark $495 million commercialization deal with Pfizer China for Ecnoglutide, a next-generation cAMP-biased GLP-1 receptor agonist. Approved for type 2 diabetes in China, it shows 15.1% placebo-adjusted weight loss in trials. This partnership aims to address rising obesity rates amid national health initiatives.
The UK Government has announced financial incentives for GPs to boost prescriptions of weight-loss injections Mounjaro and Wegovy on the NHS. Eight months into the mass rollout, not all practices are participating, prompting £25 million in funding for fairer access. Health Secretary Wes Streeting calls it a 'game changer' for obesity, but experts warn of workload risks.
